RESUMO
Heparin-induced thrombocytopenia (HIT) is immune-mediated. It occurs more frequently with unfractionated heparin (UFH) than with low molecular weight heparins (LMWH). It is associated with thromboembolic rather than hemorrhagic events, as opposed to thrombocytopenia of other etiologies. The key in therapy is the cessation of heparin and the start of another anticoagulant. We report a 58 years old female with HIT secondary to the use of Enoxaparin who was successfully managed with Rivaroxaban. Our goal is to report a novel therapy and provide the evidence that supports its use.
Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Trombocitopenia/induzido quimicamente , Trombocitopenia/tratamento farmacológico , Heparina/uso terapêutico , Inibidores do Fator Xa/uso terapêutico , Rivaroxabana/uso terapêutico , Anticoagulantes/efeitos adversos , Fatores de Risco , Resultado do Tratamento , Trombose Venosa/etiologia , Trombose Venosa/prevenção & controleRESUMO
Heparin-induced thrombocytopenia (HIT) is immune-mediated. It occurs more frequently with unfractionated heparin (UFH) than with low molecular weight heparins (LMWH). It is associated with thromboembolic rather than hemorrhagic events, as opposed to thrombocytopenia of other etiologies. The key in therapy is the cessation of heparin and the start of another anticoagulant. We report a 58 years old female with HIT secondary to the use of Enoxaparin who was successfully managed with Rivaroxaban. Our goal is to report a novel therapy and provide the evidence that supports its use.